Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda
A breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda. Moderna's CEO revealed the promising five-year results.
